Irvine, CA – According to filings with the U.S. Securities and Exchange Commission, nRichDX is raising $5,000,000.00 in new funding. Sources indicate as part of senior management Chief Executive Officer, William Curtis played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About nRichDX

nRichDX Inc, based in Irvine, CA is an emerging leader in the liquid biopsy sample prep market, delivering up to 75X more target material (ctDNA, CTCs, exosomes, etc.) than existing sample prep systems for molecular testing. The patented Revolution System is the first high-yield, IVD liquid biopsy sample prep platform that can process sample volumes from 3 mL-50 mL and offers a single solution for multiple specimen types and targets. nRichDX solves one of precision medicine’s greatest problems – inaccurate diagnostic results for up to 50% of liquid biopsy-based molecular diagnostic tests (NGS, PCR, Micro Array, etc.) due to a lack of target material. The Revolution platform greatly enhances test sensitivity and enables high confidence test results that promote earlier detection, monitoring, timely treatment and optimal patient outcomes.

To learn more about nRichDX, visit http://nrichdx.com/

Contact:
William Curtis, Chief Executive Officer
949-341-1980
wcurtis@nrichdx.com
https://www.linkedin.com/in/bill-curtis-948b92b/

SOURCE: http://www.intelligence360.io
Copyright (c) 2020 SI360 Inc. All rights reserved